GreenLight Biosciences Holdings, PBC Common Stock
GRNA
GRNA was delisted on the 21st of July, 2023.
32 hedge funds and large institutions have $95.9M invested in GreenLight Biosciences Holdings, PBC Common Stock in 2021 Q1 according to their latest regulatory filings, with 32 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$40.3M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$18.2M |
| 3 |
HCM
Highbridge Capital Management
New York
|
+$6.11M |
| 4 |
TAM
Telemark Asset Management
Boston,
Massachusetts
|
+$5.89M |
| 5 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$5.88M |
Top Sellers
GRNA Hedge Fund Activity: Q1 2021 in Review
32 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in GreenLight Biosciences Holdings, PBC Common Stock (GRNA) for Q1 2021, worth a combined $95.9M.
Buyers outnumbered sellers: 32 funds opened new GRNA positions and 0 closed out — a net gain of 32 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Hudson Bay Capital Management, opening a new position worth an estimated $40.3M.
- 32 institutional investors held GreenLight Biosciences Holdings, PBC Common Stock (GRNA) as of Q1 2021, up from 0 in Q4 2020.
- Funds reported $95.9M of GreenLight Biosciences Holdings, PBC Common Stock stock for Q1 2021.
- 32 funds opened new GreenLight Biosciences Holdings, PBC Common Stock positions in Q1 2021 and 0 closed out, a net change of +32 holders.
- The largest GreenLight Biosciences Holdings, PBC Common Stock buyer in Q1 2021 was Hudson Bay Capital Management, an estimated $40.3M added.
Based on aggregated 13F filings for Q1 2021.